Education
About Us
Working with TipRanks
Follow Us
Certara (CERT)
NASDAQ:CERT
CERT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.64 - $17.94
Previous CloseN/A
Volume176.64K
Average Volume (3M)2.28M
Market Cap
$2.22B
Enterprise Value$1.85B
Total Cash (Recent Filing)$236.59M
Total Debt (Recent Filing)$308.13M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
May 01, 2025EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding161,475,710
10 Day Avg. Volume3,329,499
30 Day Avg. Volume2,277,861
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.02
Enterprise Value/Ebitda40.39
Forecast
1Y Price Target
$14.56Price Target Upside6.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCertara preannounced results with revenue and adjusted EBITDA ahead of expectations.
Market PositionCertara's biosimulation portfolio of software & services provides significant cost & time savings for leading biopharma players.
Product InnovationCertara unveiled a new solution to help drug developers transition to using more biosimulation in preclinical safety testing, aligning with the FDA's roadmap.
Bears Say
End-Market ChallengesCertara continues to be a key player in the biosimulation space, but the end-market has not cooperated, seemingly affected by IRA concerns and a choppy funding environment.
Regulatory Services SegmentThe strategic evaluation of the regulatory services business is ongoing, indicating uncertainty in that segment.
Revenue PerformanceExpected revenue of $106.0 million came in below target, driven by lower-than-expected software sales.
---
Ownership Overview
2.23% Insiders
24.40% Mutual Funds
0.42% Other Institutional Investors
56.52% Public Companies and
Individual Investors
CERT FAQ
What was Certara’s price range in the past 12 months?
Certara lowest stock price was $8.63 and its highest was $17.94 in the past 12 months.
What is Certara’s market cap?
Certara’s market cap is $2.22B.
When is Certara’s upcoming earnings report date?
Certara’s upcoming earnings report date is May 01, 2025 which is in 2 days.
How were Certara’s earnings last quarter?
Certara released its earnings results on Feb 26, 2025. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.123 by $0.027.
Is Certara overvalued?
According to Wall Street analysts Certara’s price is currently Undervalued.
Does Certara pay dividends?
Certara does not currently pay dividends.
What is Certara’s EPS estimate?
Certara’s EPS estimate is 0.11.
How many shares outstanding does Certara have?
Certara has 161,475,710 shares outstanding.
What happened to Certara’s price movement after its last earnings report?
Certara reported an EPS of $0.15 in its last earnings report, beating expectations of $0.123. Following the earnings report the stock price went up 0.568%.
Which hedge fund is a major shareholder of Certara?
Currently, no hedge funds are holding shares in CERT
---
Certara Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.56 (6.05% Upside)
$14.56 (6.05% Upside)
Blogger Sentiment
Bullish
CERT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 414.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 8.4%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.13%
12-Months-Change
Fundamentals
Return on Equity
-1.14%
Trailing 12-Months
Asset Growth
0.77%
Trailing 12-Months
Company Description
Certara
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
---
CERT Company Deck
---
CERT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Certara's earnings call reflected a strong finish to 2024 with significant growth in software bookings and successful integration of strategic acquisitions. However, challenges such as cautious customer spending and elongated decision-making timelines dampened the overall outlook. The company's strategic investments in AI and software development are poised to drive future growth.Read More>---
CERT Stock 12 Month Forecast
Average Price Target
$14.56
▲(6.05% Upside)
Technical Analysis
---